Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ___________________________________________________________________________ Form 10-K ___________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ...

Nektar Therapeutics (NASDAQ:NKTR) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - President and Chief Executive Officer Brian Kotzin - Chief Medical Officer Jonathan Zalevsky - Chief Research and Development Officer Jillian Thomsen - Chief Financial Officer Conference Call Participants Chris Shibutani - Goldman Sachs Roger Song - Jefferies Group LLC Jessica Fye - JPMorgan Chase & Co. Greg Harrison ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Com ...

Nektar Therapeutics (NASDAQ:NKTR) Q4 2021 Earnings Conference Call February 28, 2022 5:00 PM ET Company Participants Jennifer Ruddock ??? Head-Corporate Affairs Howard Robin ??? President and Chief Executive Officer Dimitry Nuyten ??? Chief Medical Officer Jonathan Zalevsky ??? Chief-Research and Development Gil Labrucherie ??? Chief Operating Officer and Chief Financial Officer Conference Call Participants Peter Lawson ??? Barclays CJ Zopf ??? Goldman Sachs Jessica Fye ??? JPMorgan Greg Harrison ??? Bank o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ___________________________________________________________________________ Form 10-K ___________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Table of Contents 455 Mission Bay Boulevard South San Francisco, California 94158 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transi ...

Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the quarterly period ended September 30, 2021 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ...

Nektar Therapeutics (NASDAQ:NKTR) Q2 2021 Earnings Conference Call August 5, 2021 5:00 PM ET Company Participants Jennifer Ruddock - Head of Corporate Affairs Howard Robin - President and CEO Gil Labrucherie - COO and CFO Jonathan Zalevsky - Chief of Research and Development Dimitry Nuyten - Chief Medical Officer Conference Call Participants Jay Olson - Oppenheimer Jessica Fye - JPMorgan Daina Graybosch - SVB Leerink Arlinda Lee - Canaccord Operator Good day and thank you for standing by. Welcome to the Nek ...

_______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 ______________________________________________________________ ...